Program
revumenib
Also written as “Revumenib”.
Its studies are mostly in Leukemia, Myeloid, Acute · Hematologic Neoplasms · Colorectal Neoplasms · Leukemia, led by Syndax Pharmaceuticals.
Furthest: phase 3, since Sep 30, 20256 company-led studies, 4 open or runningNext primary completion: Feb 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Syndax Pharmaceuticals | 64 open or running | phase 3since Sep 30, 2025 | Aug 16, 2019 | Feb 2027phase 1 · NCT06226571 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 16, 2019First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT04065399 · 447 planned · United States, Australia, Canada and more
- Jun 1, 2022Phase 1 study in LeukemiaNCT05406817 · 9 enrolled · United States
- Feb 7, 2023Phase 2 study in Colorectal NeoplasmsNCT05731947 · 41 enrolled · United States
- Jan 12, 2024Phase 1 study in Leukemia, Myeloid, AcuteNCT06226571 · 96 enrolled · United States, Australia, Canada and more
- Sep 30, 2025Phase 3 study in Leukemia, Myeloid, AcuteNCT07211958 · 468 planned · United States, Argentina, Australia and more
- Oct 28, 2026Phase 1 study in RecurrenceNCT07923071 · 18 planned
Ahead
- Feb 2027Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06226571
- Dec 15, 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT04065399
- Jun 2029Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT07211958
- Jan 2030Primary completion: phase 1 study in RecurrenceNCT07923071
TargetBeta
“An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, ”NCIt, by rule
“Menin/Histone-lysine N-methyltransferase MLL inhibitor; Menin inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| bleximenib | Johnson & Johnson | phase 3 | 4 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07923071Recurrence | 1 | Not yet recruiting | Jan 2030 | 18 |
| NCT07211958Leukemia, Myeloid, Acute · United States, Argentina, Australia and more | 3 | Recruiting | Jun 2029 | 468 |
| NCT06226571Leukemia, Myeloid, Acute · United States, Australia, Canada and more | 1 | Active, not recruiting | Feb 2027 | 96 |
| NCT05731947Colorectal Neoplasms · United States | 2 | Terminated | Jun 30, 2025 | 41 |
| NCT05406817Leukemia · United States | 1 | Completed | Nov 18, 2024 | 9 |
| NCT04065399Leukemia, Myeloid, Acute · United States, Australia, Canada and more | 2 | Recruiting | Dec 15, 2027 | 447 |
How it is read
Names in the registry
- “Revumenib”, 5 entries
- “revumenib”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 3 studies
- Hematologic Neoplasms, 1 study
- Colorectal Neoplasms, 1 study
- Leukemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.